Some of Our Exciting New Studies Include:
KETAMINE TREATMENT
Esketmaine is a rapid acting FDA-approved antidepressant that is dosed on a weekly basis via nasal spray. Unlike any other antidepressant on the market, this medication has been found to increase neural plasticity, which aids in longer-lasting antidepressant effects. Designed specifically for treatment-resistant depression.
NOVEL ANTIDEPRESSANT
Zuranolone is a short-term, as-needed antidepressant medication. It was initially designed for postpartum depression, and has subsequently been investigated for treatment of insomnia and major depressive disorder. Zuranolone is only taken for a period of 2-weeks at a time, with antidepressant effects typically becoming noticable within the first week.
DIGITAL STUDY
This study is looking at the use of a new smartphone app, designed to help guide participants through cognitive behavioral therapy (CBT), and cognitive training. Completely remote study that can be done from the comfort of your own home!
And many more! Check out our website for a full list of active clinical trials.
No comments:
Post a Comment